Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PPARD | Q03181 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631663 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL3672434 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL30337624 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL1698301 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL4632103 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL28431607 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL2769717 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL6898473 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL4480655 | 1.00 | DGKA (0.61) | DGKALMNAALDH1A1NAAAPAM | |
| SCHEMBL11128008 | 0.98 | DGKA (0.59) | DGKALMNAALDH1A1NAAAPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108208763-A | A kind of absolute acid stability emulsion composition and preparation method thereof | 厦门金达威生物科技有限公司 | 2018-06-29 | — | — | CN | claimed |
| CN-116120173-A | Synthesis method of long-chain alkyl-beta-keto ester compound | 金浦新材料股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115942870-A | Composition with virucidal and/or antiviral activity | 西姆莱斯股份公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115551828-A | Perfume composition | 西姆莱斯股份公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115305215-A | Novel bacterial starter of the genus lactobacillus | 西姆莱斯股份公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-108208763-B | Acid-stable emulsion composition and preparation method thereof | 厦门金达威生物科技有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-108208763-A | A kind of absolute acid stability emulsion composition and preparation method thereof | 厦门金达威生物科技有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-105250237-A | Pharmaceutical composition for preparing nano/micro bubbles for drug delivery | SUNG HSING WEN | 2016-01-20 | — | — | CN | disclosed |
| CN-101616687-B | Non-specific immunostimulating agents | PEVION BIOTECH AG CH | 2013-11-20 | — | — | CN | disclosed |
| US-8367077-B2 | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof | PEVION BIOTECH, AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-1938835-A1 | Non-specific immunostimulating agents | Pevion Biotech AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20080107649-A1 | Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide | PEVION BIOTECH LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
| EP-1680446-B1 | COMPOSITIONS COMPRISING MELITTIN-DERIVED PEPTIDES AND METHODS FOR THE POTENTIATION OF IMMUNE RESPONSES AGAINST TARGET ANTIGENS | PEVION BIOTECH LTD (CH) | 2007-10-31 | — | — | EP | disclosed |
| EP-1831251-A1 | IMMUNOGENIC COMPOSITIONS OF CYCLIC PEPTIDES DERIVED FROM THE BETA-AMYLOID PEPTIDE | Pevion Biotech Ltd. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006069718-A9 | IMMUNOGENIC COMPOSITIONS OF CYCLIC PEPTIDES DERIVED FROM THE BETA-AMYLOID PEPTIDE | PEVION BIOTECH LTD (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-1680446-A2 | COMPOSITIONS COMPRISING MELITTIN-DERIVED PEPTIDES AND METHODS FOR THE POTENTIATION OF IMMUNE RESPONSES AGAINST TARGET ANTIGENS | Pevion Biotech Ltd. (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006069718-A1 | IMMUNOGENIC COMPOSITIONS OF CYCLIC PEPTIDES DERIVED FROM THE BETA-AMYLOID PEPTIDE | PEVION BIOTECH LTD. (CH) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676859-A1 | Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide | Pevion Biotech Ltd. (CH) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005049647-A2 | COMPOSITIONS COMPRISING MELITTIN-DERVED PEPTIDES AND METHODS FOR THE POTENTIATION OF IMMUNE RESPONSES AGAINST TARGET ANTIGENS | PEVION BIOTECH LTD. (CH) | 2005-06-02 | — | — | WO | disclosed |
| CN-1158063-C | Rinse-off water-in-oil-in-water compositions | ˹��������ͼ˹�����µ� | 2004-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107649-A1 | Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide | IAPP, APP, BACE1 | DGKA 4203/4885LMNA 2058/4885ALDH1A1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.